New developments in the treatment of ADHD.
Biederman
Joseph
J
Dept. of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Arnsten
Amy F T
AF
Faraone
Stephen V
SV
Doyle
Alysa E
AE
Spencer
Thomas J
TJ
Wilens
Timothy E
TE
Weiss
Margaret D
MD
Safren
Steven A
SA
Culpepper
Larry
L
D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000628:therapy*; D001559:Benzhydryl Compounds / Q000627:therapeutic use; D016642:Bupropion / Q000627:therapeutic use; D000697:Central Nervous System Stimulants / Q000627:therapeutic use; D002648:Child; D003000:Clonidine / Q000627:therapeutic use; D015928:Cognitive Behavioral Therapy / Q000639:trends; D016316:Guanfacine / Q000627:therapeutic use; D006801:Humans; D000077408:Modafinil; D018722:Nicotinic Agonists / Q000627:therapeutic use; D010819:Physician's Role; D011320:Primary Health Care; D011437:Propylamines / Q000627:therapeutic use; D016896:Treatment Outcome
D000929:Antidepressive Agents, Tricyclic; D001559:Benzhydryl Compounds; D000697:Central Nervous System Stimulants; D018722:Nicotinic Agonists; D011437:Propylamines; D016642:Bupropion; D016316:Guanfacine; D000069445:Atomoxetine Hydrochloride; D003000:Clonidine; D000077408:Modafinil